Nuvation Bio is a biopharmaceutical company developing therapies for oncology, addressing difficult-to-treat cancers.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 267,032 | $1,495,379 | 0.0% |
| David Einhorn / Greenlight | 45 | Holds (flat) | 34,995 | $195,972 | 0.0% |
| Stanley Druckenmiller / Duquesne | 91 | Trimmed -50% | 2,269,900 | $12,711 | 0.3% |
| Report | Date | Stance |
|---|---|---|
| #97 — Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami | 2025-05-28 | LONG |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.